CLOs on the Move

Diagnostic Clinic of Houston

www.diagnosticclinic.com

 
At Diagnostic Clinic, our philosphy is driven by a desire to create a physician-patient relationship that is centered on trust. While many beliefs shift with time, some should never go out of style. Diagnostic Clinic has held true to its founders' basic
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

DENTAL ARTS LABORATORY Inc

DENTAL ARTS LABORATORY Inc is a Peoria, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

G F D Courier Corp

G F D Courier Corp is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Incyte Pathology

InCyte Pathology is the premier provider of anatomic diagnostic services in the Northwest. Our state-of-the-art facility based in Spokane Valley, Washington, is owned and operated by pathologists dedicated to providing patients with comprehensive

Thoele Dental Laboratories Inc

Thoele Dental Laboratories Inc is a Waite Park, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce is developing two clinical-stage programs as well as advancing and building out its broad and wholly-owned discovery pipeline of immuno-oncology targets, including those expressed on T-regulatory cells, macrophages and stromal cells. Jounce`s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being assessed in a Phase 2 clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in combination with future pipeline products, and Jounce has completed enrollment in the JTX-4014 Phase 1 clinical trial. In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene. For more information, please visit www.jouncetx.com. We have many career opportunities at Jounce and are looking for exceptional individuals who share our passion and perseverance for developing highly durable cancer immunotherapies that can dramatically impact and improve patients` lives.